Modern radiation therapy for nodal non-Hodgkin lymphom-target definition and dose guidelines from the international lymphoma radiation oncology group
Tim Illidge,MD,PhD1, Lena Specht,MD2, Joachim Yahalom,MD3,Berthe Aleman,MD,PhD4, Anne Kiil Berthelsen,MD5,Louis Constine,MD6,Bouthaina Dabaja,MD3, Kavita Dharmarajan,MD7,Andrea Ng,MD8,Umberto Ricardi,MD9, Andrew Wirth,MD10
1Institute of Cancer Sciences,University of Manchester,Manchester Academic Health Sciences Centre,The Christie National Health Service Foundation Trust,Manchester,United Kingdom; 2Department of Oncology and Hematology,Rigshospitalet,University of Copenhagen,Copenhagen,Denmark; 3Department of Radiation Oncology,Memorial Sloan-Kettering Cancer Center,New York,New York; 4Department of Radiotherapy,The Netherlands Cancer Institute,Amsterdam,The Netherlands; 5Department of Radiation Oncology and PET Centre,Rigshospitalet,University of Copenhagen,Copenhagen,Denmark; 6Departments of Radiation Oncology and Pediatrics,James P.Wilmot Cancer Center,University of Rochester Medical Center,Rochester,New York; 7Division of Radiation Oncology,Department of Radiation Oncology,The University of Texas MD Anderson Cancer Center,Houston,Texas; 8Department of Radiation Oncology,Brigham and Women’s Hospital and Dana-Farber Cancer Institute,Harvard University,Boston,Massachusetts; 9Radiation Oncology Unit,Department of Oncology,University of Torino,Torino,Italy; and 10Division of Radiation Oncology,Peter MacCallum Cancer Institute,St. Andrews Place,East Melbourne,AustraliaCui Jianxiong,Yang Yong,Qi Shunang,TranslationDepartment of Oncology,Sichuan Provincial Crops Hospital of Chinese People’s Armed Police Forces,Leshan 614000,China (Cui JX); 2Department of Radiation Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China (Yang Y,Qi SN)
Abstract： The guidelines represent an agreed consensus view of the ILROG steering committee on the use of RT in NHL in the modern era. The roles of reduced volume and reduced doses are addressed,integrating modern imaging with 3-dimensional planning and advanced techniques of RT delivery. In the modern era,combined-modality treatment with systemic therapy is appropriate. A new concept,involved-site RT,defines the clinical target volume. For indolent NHL,often treated with RT alone,larger fields should be considered. Newer treatment techniques,including intensity modulated RT,breath holding,image guided RT,and 4-dimensional imaging,should be implemented,and their use is expected to decrease significantly the risk for normal tissue damage while still achieving the primary goal of local tumor control.
. Modern radiation therapy for nodal non-Hodgkin lymphom-target definition and dose guidelines from the international lymphoma radiation oncology group[J]. Chinese Journal of Radiation Oncology, 2017, 26(8): 845-852.
[1] Bush RS,Gospodarowicz M,Sturgeon J,et al. Radiation therapy of localized non-Hodgkin’s lymphoma[J].Cancer Treat Rep,1977,61(6):1129-1136. [2] Shi Z,Das S,Okwan-Duodu D,et al. Patterns of failure in advanced stage diffuse large B cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of con-solidative radiation therapy[J].Int J Radiat Oncol Biol Phys,2013,86:569-577. [3] Zwick C,Held G,Ziepert N,et al. The role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.results from two prospective trials of the DSHNHL[J].Haematol Oncol,2013,31(Suppl 1):137. [4] Dorth JA,Prosnitz LR,Broadwater G,et al. Impact of consolidation radiation therapy in stage Ⅲ-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging[J].Int J Radiat Oncol Biol Phys,2012,84(3):762-767.DOI:10.1016/j.ijrobp.2011.12.067. [5] Dorth JA,Chino JP,Prosnitz LR,et al. The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium 67 scans[J].Ann Oncol,2011,22(2):405-410. [6] Lowry L,Smith P,Qian W,et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma:A randomised phase Ⅲ trial.[J].Radiother Oncol,2011,100(1):86-92.DOI:10.1016/j.radonc.2011.05.013. [7] Horning SJ,Weller E,Kim K,et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lym-phoma:Eastern Cooperative Oncology Group study 1484[J].J Clin Oncol 2004,22(5):3032-3038. [8] Phan J,Mazloom A,Medeiros LJ,et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy[J].J Clin Oncol,2010,28(27):4170-4176.DOI:10.1200/JCO.2009.27.3441. [9] Yahalom J,Mauch P.The involved field is back:issues in delineating the radiation field in Hodgkin’s disease[J].Ann Oncol,2002,13(1):79-83. [10] Yu JI,Nam H,Ahn YC,et al. Involved lesion radiation therapy after chemotherapy in limited stage head and neck diffuse large B cell lymphoma[J].Int J Radiat Oncol Biol Phys,2010,78(2):507-512.DOI:10.1016/j.ijrobp.2009.07.1706. [11] Verhappen MH,Poortmans PMP,Raaijmakers E,et al. Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodg-kin’s lymphoma[J].Radiother Oncol,2013,109(1):133-139.DOI:10.1016/j.radonc.2013.07.013. [12] DeLuca P,Jones D,Gahbauer R,et al. Prescribing,recording,and reporting photon-beam intensity-modulated radiation therapy (IMRT)[report 83][J].J ICRU,2010,10(1):1-106. [13] Hoppe BS,Moskowitz CH,Filippa DA,et al. Involved-field radio-therapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma:Long-term disease control and toxicity[J].J Clin Oncol,2008,26(9):1858-1864. [14] Kahn S,Flowers C,Xu Z,et al. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?[J].Int J Radiat Oncol Biol Phys,2011,81(1):175-180.DOI:10.1016/j.ijrobp.2010.05.010. [15] Wolthaus JW,Sonke JJ,van Herk M,et al. Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients[J].Int J Radiat Oncol Biol Phys,2008,70(4):1229-1238.DOI:10.1016/j.ijrobp.2007.11.042. [16] van Herk M.Errors and margins in radiotherapy[J].Semin Radiat Oncol,2004,14(1):52-64. [17] Miller TP,Dahlberg S,Cassady R,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized inter-mediate and high grade non-Hodgkin’s lymphoma[J].N Engl J Med,1998,339(1):21-26. [18] Berthelsen AK,Holm S,Loft A,et al. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients.[J].Eur J Nucl Med Mol Imaging,2005,32(10):1167-1175. [19] Goodman KA,Toner S,Hunt M,et al. Intensity-modulated radio-therapy for lymphoma involving the mediastinum[J].Int J Radiat Oncol Biol Phys,2005,62(1):198-206. [20] Xu LM,Li YX,Fang H,et al. Dosimetric evaluation and treatment outcome of intensity modulated radiation therapy after doxorubicin-based chemotherapy for primary mediastinal large B-cell lymphoma.[J].Int J Radiat Oncol Biol Phys,2013,85(5):1289-1295.DOI:10.1016/j.ijrobp.2012.10.037. [21] Nieder C,Schill S,Kneschaurek P,et al. Influence of different treat-ment techniques on radiation dose to the LAD coronary artery.[J].Radiat Oncol,2007,2(1):20. [22] Paumier A,Ghalibafian M,Gilmore J,et al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lym-phoma[J].Int J Radiat Oncol Biol Phys,2012,82(4):1522-1527.DOI:10.1016/j.ijrobp.2011.05.015. [23] Moser EC,Noordijk EM,Carde P,et al. Late non-neoplastic events in patients with aggressive non-Hodgkin’s lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials[J].Clin Lymph Myel,2005,6(1):122-130. [24] Moser EC,Noordijk EM,van Leeuwen FE,et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma[J].Blood,2006,107(14):2912-2919. [25] Brodin NP,Vogelius IR,Maraldo MV,et al. Life years lostdcomparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale[J].Cancer,2012,118(27):5432-5440. [26] Bentzen SM,Constine LS,Deasy JO,et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC):An introduction to the scientific issues[J].Int J Radiat Oncol Biol Phys,2010,76(3 Suppl):S3-S9. [27] Specht L,Yahalom J,Illidge T,et al. Modern radiotherapy for Hodgkin lymphoma-field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)[J].Int J Radiat Oncol Biol Phys,2013,[Epub ahead of print].http://dx.doi.org/10.1016/ j.ijrobp.2013.05.005. [28] Vose JM,Zhang MJ,Rowlings PA,et al. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission:a report from the autologous blood and marrow transplant registry[J].J Clin Oncol,2001,19(2):406-413. [29] Kahn ST,Flowers CR,Lechowicz MJ,et al. Refractory or relapsed Hodgkin’s disease and non-Hodgkin’s lymphoma:optimizing involved-field radiotherapy in transplant patients[J].Cancer J,2005,11(2):425-431. [30] Hoppe BS,Moskowitz CH,Zhang Z,et al. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma[J].Bone Marrow Transplant,2009,43(12):941-948.DOI:10.1038/bmt.2008.408. [31] Biswas T,Dhakal S,Chen R,et al. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era[J].Int J Radiat Oncol Biol Phys,2010,77(1):79-85.DOI:10.1016/j.ijrobp.2009.04.036. [32] Aref A,Narayan S,Tekyi-Mensah S,et al. Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin’s lymphoma[J].Radiat Oncol Investig,1999,7(1):186-191. [33] Martens C,Hodgson DC,Wells WA,et al. Outcome of hyper-fractionated radiotherapy in chemotherapy-resistant non-Hodgkin’s lymphoma[J].Int J Radiat Oncol Biol Phys,2006,64(6):1183-1187. [34] Tseng YD,Chen Y,Catalano P,et al. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma[J].Int J Radiat Oncol Biol Phys,2013,87(2 Suppl):S60. [35] Campbell BA,Voss N,Woods R,et al. Long-term outcomes for pa-tients with limited stage follicular lymphoma:involved regional radiotherapy versus involved node radiotherapy[J].Cancer,2010,116(19):3797-3806. [36] Haas RL,Poortmans P,de Jong D,et al. Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients[J].Eur J Cancer,2005,41(12):1724-1730. [37] Girinsky T,Guillot-Vals D,Koscielny S,et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation:analysis of predictive parameters of response to treatment[J].Int J Radiat Oncol Biol Phys,2001,51(1):148-155. [38] Russo AL,Chen YH,Martin NE,et al. Low-dose involved-fieldradiation in the treatment of non-Hodgkin lymphoma:Predictorsof response and treatment failure[J].Int J Radiat Oncol Biol Phys,2013,86(1):121-127.DOI:10.1016/j.ijrobp.2012.12.024. [39] Rossier C,Schick U,Miralbell R,et al. Low-dose radiotherapy in indolent lymphoma[J].Int J Radiat Oncol Biol Phys,2011,81(1):1-6.DOI:10.1016/j.ijrobp.2010.12.062. [40] Chan EK,Fung S,Gospodarowicz M,et al. Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma[J].Int J Radiat Oncol Biol Phys,2011,81(5):e781-e786.DOI:10.1016/j.ijrobp.2010.10.013. [41] Hoskin P,Kirkwood A,Bopova B,et al. FoRT:a phase 3 multi-center prospective randomized trial of low dose radiation therapy for follic-ular and marginal zone lymphoma[J].Int J Radiat Oncol Biol Phys,2013,85(1):22.DOI:10.1016/j.ijrobp.2012.11.016.
2017, Vol. 26 
